Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1

Interventions

Cyclophosphamide 9fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 6Bortezomib 6tanespimycin 5romidepsin 5Vorinostat 5Tacrolimus 5Magnetic Resonance Spectroscopy 5Gemcitabine 5fludarabine 4Radiotherapy 4Lenalidomide 4Etoposide 4belinostat 3Whole-Body Irradiation 3Specimen Handling 3Nivolumab 3Mycophenolic Acid 3Irinotecan 3Doxorubicin 3Dasatinib 3Brentuximab Vedotin 3Biopsy 3Bendamustine Hydrochloride 3sodium-iodide symporter 2pembrolizumab 2nelarabine 2mogamulizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mycosis Fungoides × trastuzumab biosimilar HLX02 × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡